⚙
AI-generated deep summary
by claude@2026-07, 2026-07-04
· read from full text
ⓘ
The paper studied whether adeno-associated virus 9 (AAV9) can efficiently transduce podocytes as a potential gene therapy approach for Alport syndrome, using a quantitative comparison across cultured healthy vs Alport podocytes, ex vivo glomeruli, and an Alport mouse model after peripheral intravenous injection. AAV9-GFP showed similar transduction rates in healthy and Alport podocytes in culture, but ex vivo glomeruli incubated with AAV9-GFP demonstrated enhanced transduction in Alport tissue compared with wild type. In vivo, mice injected with AAV9-GFP exhibited strikingly increased transduction in Alport podocytes, which the authors attribute to a pathological environment potentially facilitating vector penetration; the main caveat is that efficacy was evaluated for transduction rather than therapeutic gene correction in patients. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Abstract
Alport syndrome is a rare genetic disorder characterized by progressive kidney disease, hearing loss, and eye abnormalities. Gene therapy for Alport syndrome has not yet been realized due to technical challenges, including effective transduction of target cells. In this study, we established a quantitative testing platform using podocytes in culture, ex vivo glomeruli, and a mouse model of Alport syndrome to evaluate the transduction efficacy of adeno-associated Virus-9 (AAV9) as a gene delivery vehicle. We compared transduction levels of AAV9-GFP vectors between healthy and Alport podocytes in culture, revealing that both cell types exhibited similar transduction rates. We then incubated ex vivo glomeruli with AAV9-GFP and found enhanced transduction in Alport compared to wild type podocytes. Finally in mice following a peripheral intravenous injection of AAV9-GFP we found a striking increase in transduction in Alport podocytes suggesting that the pathological environment may facilitate higher penetration of the vector. These findings underscore the potential of AAV9 for effective gene delivery in the context of Alport syndrome, providing a foundation for future therapeutic strategies aimed at correcting the underlying genetic defects. Plain Language Summary This study highlights the clinical significance of AAV9 as a potential gene delivery vehicle for Alport syndrome treatment. Our findings demonstrate that Alport podocytes exhibit enhanced transduction levels in ex vivo and in vivo environments compared to healthy podocytes. This suggests that AAV9 could effectively target podocytes in Alport syndrome, paving the way for innovative gene therapy strategies that may improve patient outcomes and quality of life.
Full text
2,524 characters
· extracted from
oa-doi-fallback
· click to expand
Abstract
Alport syndrome is a rare genetic disorder characterized by progressive kidney disease, hearing loss, and eye abnormalities. Gene therapy for Alport syndrome has not yet been realized due to technical challenges, including effective transduction of target cells. In this study, we established a quantitative testing platform using podocytes in culture, ex vivo glomeruli, and a mouse model of Alport syndrome to evaluate the transduction efficacy of adeno-associated Virus-9 (AAV9) as a gene delivery vehicle. We compared transduction levels of AAV9-GFP vectors between healthy and Alport podocytes in culture, revealing that both cell types exhibited similar transduction rates. We then incubated ex vivo glomeruli with AAV9-GFP and found enhanced transduction in Alport compared to wild type podocytes. Finally in mice following a peripheral intravenous injection of AAV9-GFP we found a striking increase in transduction in Alport podocytes suggesting that the pathological environment may facilitate higher penetration of the vector. These findings underscore the potential of AAV9 for effective gene delivery in the context of Alport syndrome, providing a foundation for future therapeutic strategies aimed at correcting the underlying genetic defects.
Plain Language Summary This study highlights the clinical significance of AAV9 as a potential gene delivery vehicle for Alport syndrome treatment. Our findings demonstrate that Alport podocytes exhibit enhanced transduction levels in ex vivo and in vivo environments compared to healthy podocytes. This suggests that AAV9 could effectively target podocytes in Alport syndrome, paving the way for innovative gene therapy strategies that may improve patient outcomes and quality of life.
Competing Interest Statement
The authors declare the following conflicts of interest: R.L., D.R.S, E.W., M.F., G.B., A.A., A.S. and K.G. work on a collaborative research project funded by FourPoints Innovation, a portfolio company of certain funds managed by Deerfield Management Company, L.P. R.L. has the following additional disclosures: Clinical trials PI: Bayer, Travere, River3Renal, Calliditas. Collaborative research agreements: Calliditas, Novo Nordisk.
Footnotes
↵* Joint first authors
emily.williams{at}manchester.ac.uk; maryline.fresquet{at}manchester.ac.uk; gema.bolasgonzales-lliberos{at}manchester.ac.uk; shota.kaseda{at}manchester.ac.uk
kgoncalves{at}deerfield.com; asteinsapir{at}deerfield.com
antony.adamson{at}manchester.ac.uk
david.sherwood{at}duke.edu
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.